Showing results (71-80 of 97) with videos related to
Sort By:
Pageof 10
Expert Opinion on Biological Therapy|July 28, 2016
The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic reviewGiuseppe Di Lorenzo, Sabino De Placido, Martina Pagliuca, et al.Future Oncology (London, England)|May 31, 2013
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancerCarlo Buonerba, Gregory R Pond, Guru Sonpavde, et al.Breast (Edinburgh, Scotland)|June 17, 2020
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)Laura Orlando, Vito Lorusso, Francesco Giotta, et al.BJU International|July 2, 2010
Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancerGiuseppe Di Lorenzo, Carlo Buonerba, Adriana Faiella, et al.Breast (Edinburgh, Scotland)|April 14, 2024
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trialLaura Orlando, Evaristo Maiello, Michele Orditura, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancerGiuseppe Di Lorenzo, Giacomo Cartenì, Riccardo Autorino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2023
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Giancarlo Bisagni, Federico Piacentini, et al.Journal of Geriatric Oncology|February 6, 2014
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancerUgo De Giorgi, Karim Rihawi, Michele Aieta, et al.Clinical Genitourinary Cancer|December 28, 2013
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysisUgo De Giorgi, Emanuela Scarpi, Cosimo Sacco, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2013
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registryPaolo Pedrazzoli, Giovanni Martinelli, Alessandro Massimo Gianni, et al.Pageof 10